0000000000793481

AUTHOR

Athanasios Tsianakas

showing 2 related works from this author

Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma

2011

Objective  The aim of this study was to evaluate the safety and efficacy profile of pegylated interferon α-2b (PEG-IFN α-2b) in combination with photochemotherapy (PUVA) in the treatment of cutaneous T-cell lymphoma (CTCL) in comparison with standard IFN α plus PUVA. Design  Retrospective cohort study over a period of 7 years. Patients and interventions  A total of 17 consecutive CTCL patients (stage IA–IV) were retrospectively analysed for toxicity and response rates associated with PEG-IFN α-2b (1.5 μg/kg weekly) plus PUVA (n = 9) or standard IFN α-2a (9 MIU 3×/week) plus PUVA (n = 8). Main outcome measures  Differences of response rates (complete/partial remission), progression-free surv…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCutaneous T-cell lymphomaDermatologymedicine.diseaseDermatologyGastroenterologyDiscontinuationchemistry.chemical_compoundInfectious DiseaseschemistryPegylated interferonInternal medicinePUVA therapyToxicitymedicinebusinessProspective cohort studyAdverse effectPsoralenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.

2016

Objective The aim of the study was to assess the efficacy and safety of fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 patients with CLE, refractory to topical corticosteroids, were included. The primary endpoint of the study was the evaluation of the efficacy of FAEs after 24 weeks of treatment as assessed by the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI). Results Compared to baseline, significant improvement in the mean total RCLASI activity score and the mean RCLASI activity score for skin lesions was observed in week 12 ( p = 0.002, p = 0.002, respectively) …

AdultMaleFumaric acidmedicine.medical_specialtyColicPilot ProjectsSeverity of Illness IndexDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRheumatologyFumaratesLupus Erythematosus CutaneousMedicineHumansIn patientProspective Studies030203 arthritis & rheumatologybusiness.industryHeadacheMiddle AgedDermatologyAlternative treatmentClinical trialTreatment OutcomeFumaric Acid EsterschemistryCutaneous Lupus ErythematosusFemaleOpen labelbusinessLupus
researchProduct